All studies
AuthorisedTherapeutic use (Phase IV)Interventional

PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial

After a liver transplant, patients must take medicines called immunosuppressants to stop their body rejecting the new liver. Common medicines include tacrolimus and mycophenolic acid. However, balancing these drugs is difficult. Too little medicine risks organ rejection, while too much can harm the kidneys, raise blood pressure, or cause diabetes. The PRIMO trial explores whether a 'precision medicine' approach works better than routine care. This means doctors use detailed blood tests to carefully tailor drug doses to each individual patient. Researchers will monitor participants for one full year after their transplant. They will check if this personal approach keeps the liver working well, preserves kidney health, and cuts down on unwanted side effects. The goal is to help transplant patients live healthier, longer lives with fewer medication-related complications.

At a glance

Status
Authorised
Phase
Therapeutic use (Phase IV)
Sponsor
Centre Hospitalier Universitaire De Rennes
Enrolment target
454
Start
01 Oct 2026

What is this study about?

A liver transplant is a life-saving operation, but the journey does not stop after surgery. Because the immune system sees the new liver as foreign, it naturally tries to attack it. To prevent this, patients must take daily anti-rejection medicines such as tacrolimus and mycophenolic acid. While these drugs are vital, they require a very careful balancing act.

Taking too much anti-rejection medication can place heavy stress on other parts of the body. Over time, it can cause kidney damage, high blood pressure, nerve irritation, or new-onset diabetes. On the other hand, taking too little can lead to organ rejection. Currently, doctors monitor drug levels using standard tests, but what works well for one person might not be ideal for another.

The PRIMO study tests a precision monitoring system. By measuring how each patient's body processes these medicines, doctors hope to prescribe the exact dose needed—neither too high nor too low. Researchers will compare this tailored approach against standard monitoring methods to see which keeps patients healthier over their first year.

If successful, this trial could change the way post-transplant care is delivered. It could help people keep their donor liver safe for longer while reducing long-term complications and hospital visits, giving patients a better quality of life.

Key takeaways

  • The PRIMO study aims to make anti-rejection medicine dosing safer and more personal.
  • It tests tailored blood monitoring against standard monitoring over one year.
  • The main goals are protecting the new liver while reducing kidney damage, diabetes, and high blood pressure.
  • Open to adults aged 18 and over receiving a liver transplant.
  • Taking part is voluntary and does not replace your core transplant care.

Who may be eligible?

This trial is for adults aged 18 and over who are undergoing a liver transplant and need immunosuppressive treatment. Both men and women can take part.

Participants must be prescribed standard anti-rejection medicines, specifically tacrolimus and mycophenolic acid, as part of their transplant recovery plan.

Your transplant care team will look at your overall health to decide if the trial is safe and suitable for you. People with certain complex medical conditions or those unable to attend regular hospital follow-up visits may not be able to join.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I am having or have recently had a liver transplant.
  3. My care plan includes the medicines tacrolimus and mycophenolic acid.
  4. I am able to attend regular hospital check-ups for at least one year.
Answer every question to see your result.

What does participation involve?

If you take part, your study team will monitor you for one full year following your liver transplant. You will take your prescribed anti-rejection medicines as directed by your doctors. You will attend regular hospital appointments where the team will take blood samples to measure medicine levels, kidney function, and blood sugar. You will also have routine health checks, such as blood pressure measurements, and will be asked to fill in brief questionnaires about your general well-being and daily quality of life.

Potential risks and benefits

A potential benefit is having your medication levels monitored very closely, which could help protect your new liver and reduce drug side effects like kidney strain or diabetes. The risks are similar to routine post-transplant care, including minor discomfort or bruising from blood tests, and the usual side effects of anti-rejection medicines. Your participation is completely voluntary, and you are free to leave the study at any time without your normal medical care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France

Common questions

Why do I need anti-rejection medicines after a transplant?

Your immune system naturally defends your body against foreign cells. Anti-rejection drugs gently lower this immune response so your body accepts and protects the new donor liver.

What is 'precision monitoring'?

Precision monitoring uses detailed blood tests to see exactly how your body absorbs and breaks down medicines, allowing doctors to tailor doses specifically to you.

Will I receive a different medication in this trial?

No, you will receive standard transplant medicines (tacrolimus and mycophenolic acid). The trial tests how closely and precisely your doses are adjusted.

How long will I be involved in the study?

The study follows your recovery and medication levels for one year following your liver transplant.

What happens if I decide I no longer want to take part?

You can leave the study at any point. You will continue to receive standard NHS post-transplant care, and your relationship with your medical team will not change.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.